English  |  正體中文  |  简体中文  |  Items with full text/Total items : 65231/98744 (66%)
Visitors : 31974982      Online Users : 2500
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library & TKU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: https://tkuir.lib.tku.edu.tw/dspace/handle/987654321/127726


    Title: A framework to predict second primary lung cancer patients by using ensemble models
    Authors: Huang, Yen-Chun;Ho, Chieh-Wen;Chou, Wen-Ru;Chen, Mingchih
    Keywords: SPLC;Lung cancer;NHIRD;Feature selection;SMOTE;Ensemble models
    Date: 2023-12-14
    Issue Date: 2025-09-15 12:07:10 (UTC+8)
    Abstract: Machine learning (ML) model prediction, which has been wildly used in healthcare industry recently, serves as a tool to help users to make quick decisions. The prediction results could improve treatment outcomes and reduce the medical expenses. This research proposed the ML-based decision tool to predict the second primary lung cancer probability within lung cancer patients. This tool included following stages: The first stage is data processing to select the target patients by using National Health Insurance Research Database from 2011 to 2016 period as study. The second stage has used synthetic minority oversampling technique (SMOTE) to make data balancing. The third stage is feature selecting, and in final stage, we have applied five ML algorithms, which is included: Logistic Regression (LGR), Decision Tree, Random Forests (RF), multivariate adaptive regression splines (MARS), and extreme gradient boosting (XGBoost) with optimal features, then followed by building ensemble models. The results show that after feature selection, the ensemble models yield an accuracy rate 0.932. Different types of therapy (Chemotherapy (CH); Radiotherapy (RT), tyrosine kinase inhibitor (TKI)), different clinical stages, and Epidermal Growth Factor Receptor (EGFR) states were the top five optimal features affecting developed second primary lung cancer. This study can help physicians to identify the possibility with second primary lung cancer patients and make complete treatment plans for them.
    Relation: Annals of Operations Research 348, p.373-397
    DOI: 10.1007/s10479-023-05691-x
    Appears in Collections:[人工智慧學系] 期刊論文

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML112View/Open

    All items in 機構典藏 are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library & TKU Library IR teams. Copyright ©   - Feedback